Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Overview of attention for article published in Diabetology & Metabolic Syndrome, July 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

So far, Dimensions has found 158 publications that cite this research output.

Article in Diabetes Obesity and Metabolism (May 2024)

Article in Heliyon (April 2024)

Article in Clinical and Experimental Pharmacology and Physiology (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.